NORTH CHICAGO, Ill., July 18, 2014 /PRNewswire/ -- On July 18, 2014, AbbVie issued an infographic highlighting AbbVie and Shire's complementary fit and the benefits of the proposed combination.
A copy of the infographic materials will be available on AbbVie's website at: http://www.abbvieinvestor.com/phoenix.zhtml?c=251551&p=irol-disclaimer-documents
In accordance with Rule 30.4 of the Takeover Code, a copy of this announcement will be available on AbbVie's website at http://www.abbvieinvestor.com/phoenix.zhtml?c=251551&p=irol-disclaimer-documents.
AbbVie is a global, research-based biopharmaceutical company formed in January 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries. AbbVie is traded on the New York Stock Exchange under "ABBV". Additional information is available on the company's website at www.abbvieinvestor.com.
The directors of AbbVie accept responsibility for the information contained in this document and, to the best of their knowledge and belief (having taken all reasonable care to ensure that such is the case), the information contained in this document is in accordance with the facts and it does not omit anything likely to affect the import of such information.
J.P. Morgan Securities LLC ("J.P. Morgan"), together with its affiliate J.P. Morgan Limited (which conducts its
|SOURCE AbbVie Inc.|
Copyright©2014 PR Newswire.
All rights reserved